Department of Neurology, University Hospital, Cracow, Poland. Aleksandra.Klimkowicz @ mp.pl
Dement Geriatr Cogn Disord. 2011;32(1):26-31. doi: 10.1159/000330343. Epub 2011 Aug 5.
Acetylcholinesterase inhibitors (AChEIs) are the treatment of choice for patients with Alzheimer's disease (AD). However, their efficacy is moderate and differs from patient to patient. Recent studies suggest that the Q192R variant of the paraoxonase 1 gene (PON1) might affect individual susceptibility to these drugs.
We investigated the influence of 3 single nucleotide polymorphisms (SNPs) in PON1 (rs 662, rs 854560, rs 705381) and the APOE common polymorphism in 101 Polish patients with late-onset AD in response to treatment with AChEIs.
No significant differences were observed between carriers and non-carriers of the PON1 SNPs or the APOE common polymorphism in terms of treatment response. These results did not change after stratification of APOE status.
Our results suggest that both the investigated PON1 and APOE common SNPs do not influence treatment response to AChEIs in patients with AD.
乙酰胆碱酯酶抑制剂（AChEIs）是治疗阿尔茨海默病（AD）患者的首选药物。然而，其疗效是中等的，并且因人而异。最近的研究表明，对氧磷酶 1 基因（PON1）的 Q192R 变体可能会影响个体对这些药物的敏感性。
我们研究了 PON1 中的 3 个单核苷酸多态性（SNPs）（rs662、rs854560、rs705381）和 APOE 常见多态性在 101 名波兰晚发性 AD 患者对 AChEIs 治疗反应中的影响。
在治疗反应方面，PON1 SNPs 或 APOE 常见多态性的携带者和非携带者之间未观察到显著差异。在对 APOE 状态进行分层后，这些结果没有改变。
我们的结果表明，研究中发现的 PON1 和 APOE 常见 SNP 均不会影响 AD 患者对 AChEIs 的治疗反应。
